Alpha Compute Future Growth

Future criteria checks 2/6

Alpha Compute is forecast to grow earnings and revenue by 36.7% and 82.8% per annum respectively while EPS is expected to grow by 129.8% per annum.

Key information

36.7%

Earnings growth rate

129.75%

EPS growth rate

Biotechs earnings growth	28.8%
Revenue growth rate	82.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	17 Aug 2026

Recent future growth updates

Recent updates

Narrative Update • Sep 09

ALP: Pennsylvania Data Center Campus Plans Will Drive Future Upside

Analysts have raised their fair value estimate for Alpha Compute from $0.25 to $12.50, citing slightly higher discount rate assumptions, a modestly stronger projected profit margin, and an updated future P/E framework as the key drivers of the new price target. What’s in the News for Alpha Compute Alpha Compute plans a 1-for-50 stock split or significant stock dividend, scheduled for September 9, 2026.

New Narrative • Aug 20

Confidential Computing And Real Asset Financing Will Support Long Term AI Infrastructure Upside

Catalysts About Alpha Compute Alpha Compute provides GPU based confidential computing infrastructure for AI workloads across enterprise, government and consumer applications. What are the underlying business or industry changes driving this perspective?

Seeking Alpha • Aug 29

Portage Biotech GAAP EPS of -$0.13

Portage Biotech press release (NASDAQ:PRTG): Q1 GAAP EPS of -$0.13. As of June 30, 2022, the Company had cash and cash equivalents of approximately $21.2 million.

Seeking Alpha • Jul 20

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech (NASDAQ:PRTG) stock has added 16.8% to $10.95 in Wednesday morning trading, after the company said it had acquired the remaining ownership interest in its invariant natural killer T cell (iNKT cell) agonist platform. iNKT cells play an important role in anti-tumor immune responses. PRTG's synthetic iNKT agonists activate and expand important immune system components and immune attacks against cancer. With the acquisition of the about 22% remaining ownership interest, PRTG now fully owns the worldwide rights to its iNKT agonists, including lead programs PORT-2 and PORT-3. The acquisition was done through PRTG's unit iOx Therapeutics from the founding equity holders in exchange for 1.07M shares of Portage (PRTG). Additionally, a payment of $25M in PRTG shares or cash would be triggered upon the achievement of a certain clinical milestone in the PORT-2 or PORT-3 programs.

Seeking Alpha • Jul 06

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech (NASDAQ:PRTG) on Wednesday said it would acquire privately-held Tarus Therapeutics in exchange for about 2.4M PRTG shares and the assumption of $3M in liabilities. The acquisition of Tarus allows PRTG to acquire two clinical-stage adenosine compounds and two preclinical assets for a ~$21M upfront consideration. The deal also calls for additional payments of up to $32M in PRTG shares or cash upon achievement of certain milestones. As per the deal, Robert Glassman, a former independent director of Tarus, will join PRTG's board. PRTG also said it had entered into a committed share purchase agreement for up to $30M with Chicago-based institutional investor Lincoln Park Capital Fund LLC, the proceeds of which will potentially extend PRTG's cash runway into 2024. PRTG stock earlier closed +2.5% at $7.72.

Earnings and Revenue Growth Forecasts

NasdaqCM:ALP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2028	23	-19	N/A	-9	1
3/31/2027	18	-20	N/A	-2	1
3/31/2026	0	-39	-31	-21	N/A
12/31/2025	0	-27	-17	-12	N/A
9/30/2025	N/A	-15	-4	-4	N/A
6/30/2025	N/A	-11	-4	-4	N/A
3/31/2025	N/A	-7	-5	-5	N/A
12/31/2024	N/A	-30	-7	-7	N/A
9/30/2024	N/A	-67	-10	-10	N/A
6/30/2024	N/A	-71	-13	-13	N/A
3/31/2024	N/A	-75	-14	-14	N/A
12/31/2023	N/A	-145	-16	-16	N/A
9/30/2023	N/A	-113	-15	-15	N/A
6/30/2023	N/A	-109	-13	-13	N/A
3/31/2023	N/A	-105	-12	-12	N/A
12/31/2022	N/A	-17	-10	-10	N/A
9/30/2022	N/A	-14	-9	-9	N/A
6/30/2022	N/A	-16	-7	-7	N/A
3/31/2022	N/A	-17	-7	-7	N/A
12/31/2021	N/A	-21	-5	-5	N/A
9/30/2021	N/A	-19	-5	-5	N/A
6/30/2021	N/A	-18	-5	-5	N/A
3/31/2021	N/A	-16	-4	-4	N/A
12/31/2020	N/A	-6	-4	-4	N/A
9/30/2020	N/A	-6	-4	-4	N/A
6/30/2020	N/A	-5	-3	-3	N/A
3/31/2020	N/A	-5	-4	-4	N/A
12/31/2019	N/A	-6	N/A	-3	N/A
9/30/2019	N/A	-5	N/A	-3	N/A
6/30/2019	N/A	-4	N/A	-2	N/A
3/31/2019	N/A	-3	N/A	-1	N/A
12/31/2018	N/A	124	N/A	-1	N/A
9/30/2018	N/A	124	N/A	-1	N/A
6/30/2018	N/A	124	N/A	-1	N/A
3/31/2018	N/A	124	N/A	-1	N/A
12/31/2017	N/A	-10	N/A	2	N/A
9/30/2017	N/A	-16	N/A	2	N/A
6/30/2017	N/A	19	N/A	2	N/A
3/31/2017	N/A	16	N/A	-1	N/A
12/31/2016	N/A	24	N/A	-6	N/A
9/30/2016	N/A	27	N/A	-7	N/A
6/30/2016	N/A	-8	N/A	-8	N/A
3/31/2016	N/A	-6	N/A	-6	N/A
12/31/2015	N/A	-6	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALP's revenue (82.8% per year) is forecast to grow faster than the US market (13.5% per year).

High Growth Revenue: ALP's revenue (82.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/10 23:27
End of Day Share Price	2026/09/10 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alpha Compute Corp is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Justin Walsh	B. Riley Securities, Inc.
Li Wang Watsek	Cantor Fitzgerald & Co.
Kevin Dede	H.C. Wainwright & Co.

Alpha Compute Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 22% to US$140

Price target decreased by 16% to US$16.00

Recent updates

ALP: Pennsylvania Data Center Campus Plans Will Drive Future Upside

Alpha Compute Corp. Receives Additional 180 Day Period from Nasdaq to Regain Compliance with Minimum Bid Price Requirement

High number of new and inexperienced directors

Confidential Computing And Real Asset Financing Will Support Long Term AI Infrastructure Upside

Alpha Compute Corp. Announces Appointment of Mike Huskins as Independent Director and Audit Committee Member, Effective August 19, 2026

Alpha Compute Corp. Announces Management Changes

Alpha Compute Corp. Announces Appointment of Enzo Villani as President, Effective July 16, 2026

Alpha Compute Corp to Report Fiscal Year 2026 Results on Jul 15, 2026

New major risk - Share price stability

Alpha Compute Confirms That Its First Large-Scale GPU Cluster Is Now in Final Testing and Is Targeted to Hand over to AI Compute Customers on May 8, 2026

Alpha Compute Corp. Appoints Tom Richer to Advisory Board

AlphaTON Capital Corp. announced that it expects to receive $43 million in funding from Vertical Data Inc.

AlphaTON Capital Corp. has filed a Follow-on Equity Offering in the amount of $400 million.

Less than half of directors are independent

AlphaTON Capital Corp. Announces Board Changes, Effective February 6, 2026

AlphaTON Capital Corp. Launches Claude Connector Powered by TON & Telegram

AlphaTON Capital Corp. has completed a Follow-on Equity Offering in the amount of $14.999023 million.

AlphaTON Capital Corp. has filed a Follow-on Equity Offering in the amount of $14.999023 million.

New major risk - Market cap size

AlphaTON Capital Corp. Announces the Appointment of Logan Ryan Golema as Chief Technology Officer

Cyncado Therapeutics and Tarus Therapeutics, Llc Announces A Non-Binding Letter of Intent (Loi)

AlphaTON Capital Corp. Appoints William De’Ath as Chief Partnership Officer

Tarus Therapeutics, LLC Announces A Poster Presentation At the Society for Immunotherapy of Cancer Annual Meeting

AlphaTON Capital Corp and Tarus Therapeutics, LLC Announces Preclinical Mesothelioma Data Show Direct A2b Tumor Activity

AlphaTON Capital Corp. Appoints Wes Levitt as Chief Financial Officer, October 24, 2025

AlphaTON Capital Corp and Cyncado Therapeutics Announce First Evidence That Selective A2b Receptor Inhibition Lowers Pd-L1 Tumor Expression and Directly Suppresses Mesothelioma Tumor Growth

Alphaton Capital Corp. Launches Ai Vertical with Morpheusai to Accelerate Agentic Ai Development on Ton and Telegram

New major risk - Share price stability

AlphaTON Capital Corp. (NasdaqCM:ATON) entered into a non-binding letter of intent to acquire 51% stake in Gamee Limited from Animoca Brands Limited.

AlphaTON Capital Corp. announced that it has received $36.2136 million in funding

Less than half of directors are independent

Portage Biotech Inc. has filed a Follow-on Equity Offering in the amount of $2.84145 million.

New major risk - Negative shareholders equity

Portage Biotech Inc. has filed a Follow-on Equity Offering in the amount of $3.37725 million.

New major risk - Market cap size

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of Port-7

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

New major risk - Shareholder dilution

Portage Biotech Receives Extension of Time to Attain Compliance with Stock Exchange Continued Listing Requirements

Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc

New major risk - Revenue and earnings growth

Less than half of directors are independent

Portage Biotech Inc. Appoints Alexander Pickett as Chief Executive Officer, Effective December 15, 2024

Portage Biotech Inc. Appoints Alexander Pickett to Board of Directors, Effective December 15, 2024

Price target decreased by 22% to US$140

Portage Biotech Inc. Announces Chief Financial Officer Changes

Portage Biotech Inc. announced delayed 20-F filing

Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives

New major risk - Financial position

New major risk - Market cap size

Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting

New major risk - Revenue and earnings growth

New major risk - Share price stability

Price target decreased by 16% to US$16.00

Portage Biotech Inc. Announces First Patient Dosed in Phase 1A Trial of Portage-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead Inkt Engager, Port-2, in A Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer At the 2023 American Society for Clinical Oncology (Asco) Annual Meeting

Portage Biotech Inc. Presents Updated Data on the Phase 1/2 Trial Evaluating Port-2 At the Society for Immunotherapy of Cancer’S (Sitc) 37Th Annual Meeting

Portage Biotech Inc., Annual General Meeting, Nov 10, 2022

Portage Biotech Inc. Provides Research and Development Update

Portage Biotech GAAP EPS of -$0.13

Portage Biotech Inc. Announces Leadership Updates

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech Inc. (NasdaqCM:PRTG) signed an agreement to acquire Tarus Therapeutics, Inc. for $53.3 million.

Robert Glassman to Join Portage Biotech Inc. Board of Directors

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Portage Biotech Inc. Provides an Update on Its Clinical Development Programs and Announces Its Development Goals for the Remainder of 2022

Portage Biotech Announces Executive Changes

Portage Biotech Inc. Highlights First Patient Dosed in Imp-Mel Study of Port-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (Nsclc)

Portage Biotech Inc. has completed a Follow-on Equity Offering in the amount of $23 million.

Portage Biotech Inc. Highlights Safety and Survival Data from Intensity Therapeutics' It-01 Study of Int230-6 (Port-1) At Asco 2021 Annual Meeting

Juvenescence Ltd. acquired Portage pharmaceuticals Ltd from Portage Biotech Inc. (NasdaqCM:PRTG).

Portage Biotech's Common Shares Deleted from Other OTC